Atlas Trials

Combining Ipilimumab, Degarelix, and Radical Prostatectomy in Men With Newly Diagnosed Metastatic Castration Sensitive Prostate Cancer or Ipilimumab and Degarelix in Men With Biochemically Recurrent Castration Sensitive Prostate Cancer After Radical Prostatectomy

Clinical trial NCT02020070 · COMPLETED

Trial details

NCT number
NCT02020070
Sponsor
Memorial Sloan Kettering Cancer Center
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
Metastatic Castration Sensitive Prostate Cancer
Start date
2013-12-18
Primary completion
2026-06-30
Enrollment
16

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.